Database Query Results : Aspirin -acetylsalicylic acid, , PGE2

ASA, Aspirin -acetylsalicylic acid: Click to Expand ⟱
Features: nonsteroidal anti-inflammatory drug (NSAID)
Aspirin irreversibly inhibits COX-1 and modifies the enzymatic activity of COX-2. COX-2 normally produces prostanoids, most of which are proinflammatory.

-Aspirin irreversibly inhibits the enzyme cyclooxygenase-1 (COX-1). This inhibition reduces the production of thromboxane A₂, a potent promoter of platelet aggregation.
-low-dose aspirin is frequently used for the prevention of cardiovascular events such as heart attacks and strokes in individuals at risk.

Aspirin (acetylsalicylic acid; ASA) — an acetylating salicylate NSAID that irreversibly inhibits cyclooxygenase (COX) enzymes, producing anti-inflammatory, analgesic/antipyretic, and (at low dose) antiplatelet effects via sustained suppression of platelet thromboxane A₂ (TXA₂). It is a small-molecule oral drug (OTC and prescription formulations; immediate-release and enteric-coated). Standard abbreviations include ASA and “low-dose aspirin” (typically 75–100 mg/day in many guidelines/trials). In cancer biology, the most industry-relevant hypotheses center on platelet COX-1/TXA₂ suppression (metastasis/immune effects) plus COX-2/PGE₂ suppression (inflammatory tumor microenvironment), with clinical signals that are context- and biomarker-dependent.

Primary mechanisms (ranked):

  1. Platelet COX-1 acetylation → TXA₂ ↓ → platelet activation/aggregation ↓ (systemic antiplatelet axis; downstream effects on thrombosis and platelet–tumor biology)
  2. COX-2 activity modulation/inhibition → prostanoid signaling (including PGE₂) ↓ (anti-inflammatory and tumor-microenvironment effects; more dose/context dependent than platelet COX-1)
  3. Platelet-derived TXA₂ immunosuppression axis ↓ (T-cell suppression relieved; metastasis permissiveness reduced) (context-dependent; mechanistically linked to platelet COX-1/TXA₂)
  4. Immune checkpoint/inflammation coupling: PD-L1 ↓ and inflammatory mediators ↓ (model- and tissue-dependent; partly COX/prostanoid-linked and partly epigenetic/transcriptional)
  5. Pro-apoptotic balance shift in some models (BAX ↑, Bcl-2 ↓, apoptosis ↑) (secondary; model-dependent)

Bioavailability / PK relevance: Oral absorption is generally rapid (formulation-dependent). Aspirin itself is short-lived in plasma due to rapid deacetylation to salicylate, while platelet COX-1 inhibition persists for the platelet lifespan (functional persistence despite short plasma exposure). Salicylate elimination can become dose-dependent (capacity-limited) at higher doses, extending effective half-life and increasing toxicity/bleeding risk.

In-vitro vs systemic exposure relevance: Many anti-proliferative or direct tumor-cell cytotoxic effects reported in vitro occur at concentrations not typically achieved with low-dose antiplatelet regimens; clinically plausible cancer effects at low dose are more consistent with platelet/immune/microenvironment mechanisms than direct tumor cytotoxicity.

Clinical evidence status: Strong clinical use exists for antiplatelet indications (cardiovascular secondary prevention and other clinician-directed uses). For primary prevention, contemporary guidance restricts initiation due to bleeding risk (age/risk stratified). For oncology, evidence supports chemopreventive associations (strongest for colorectal cancer in long-term use) and emerging biomarker-stratified adjuvant signals (e.g., PI3K-pathway–altered CRC recurrence reduction in a large randomized setting), but this is not universal across populations and may be age- and context-dependent.

**There is debate about the reduced cancer risk effects of aspirin when used long term (10yr). The evidence is stronger for CRC especially for those with IBD. Evidence is more debatable for those 70yrs old. Also there are claims about the anti-Metastasis capabilites of aspirin for those with cancer.

Mechanistic and translation-relevant axes for aspirin (ASA) in cancer

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Platelet COX-1 → TXA₂ Indirect: platelet shielding of CTCs ↓; platelet-assisted extravasation/metastatic seeding ↓ (context-dependent) Platelet aggregation ↓; hemostasis capacity ↓ (bleeding risk ↑) P Antiplatelet state via irreversible COX-1 acetylation High mechanistic centrality at low dose because platelets cannot resynthesize COX-1; effects persist beyond plasma aspirin exposure.
2 COX-2 → PGE₂ inflammatory tumor microenvironment Inflammatory prostanoid signaling ↓; pro-tumor inflammation ↓ (dose/context dependent) GI mucosal protection ↓ (ulcer/bleeding risk ↑); renal prostaglandin effects (risk in susceptible patients) R Anti-inflammatory prostanoid suppression COX-2 modulation is less selectively targeted than platelet COX-1 at “low-dose”; relevance increases with higher systemic exposure.
3 Platelet TXA₂ → T-cell suppression axis Anti-metastatic immunity ↑ (T-cell effector function ↑; metastasis permissiveness ↓) Immune modulation ↔ (context-dependent) R Release of T-cell suppression linked to platelet TXA₂ Mechanistic bridge between antiplatelet action and metastasis control; aligns with platelet-first hypothesis for low-dose aspirin.
4 PI3K-pathway–altered CRC recurrence signal Recurrence risk ↓ in PI3K-altered localized CRC (biomarker-stratified benefit) Systemic bleeding risk ↑ remains G Genotype-linked clinical leverage (adjuvant context) Represents actionable stratification logic: benefit concentrated in molecular subsets rather than pan-CRC.
5 Immune checkpoint coupling: PD-L1 PD-L1 ↓ (model-dependent) → immune evasion ↓ (context-dependent) Immune effects ↔ G Potential immunomodulatory adjunct axis Reported in specific tumor models via transcription/epigenetic regulators; translation likely tumor-type and context dependent.
6 Apoptosis balance Apoptosis ↑; BAX ↑; Bcl-2 ↓ (model-dependent) Cell stress/irritation ↔ (context-dependent) G Secondary pro-death signaling in some models Often requires higher concentrations than antiplatelet dosing; treat as supportive rather than primary for real-world low-dose exposure.
7 Clinical Translation Constraint Benefit heterogeneity ↑ (tumor subtype, age, bleeding risk, concomitant therapy) GI bleeding ↑; hemorrhagic stroke risk ↑ (baseline-dependent); hypersensitivity in susceptible patients G Therapeutic window constrained by bleeding and population selection Major limiter for preventive use in older adults; drug–drug interactions (anticoagulants/other NSAIDs) and peri-procedural management are practical constraints.

TSF legend: P: 0–30 min   R: 30 min–3 hr   G: >3 hr
PGE2, Prostaglandin E2: Click to Expand ⟱
Source:
Type:
Prostaglandin E2 (PGE2) is a lipid compound that plays a significant role in various physiological processes, including inflammation, immune response, and regulation of cell growth. PGE2 is often found at elevated levels in various types of cancer, including colorectal, breast, and lung cancers. It can promote tumor growth by enhancing cell proliferation, inhibiting apoptosis (programmed cell death), and promoting angiogenesis (the formation of new blood vessels).
- PGE2 is a pain-inducing factor. It is able to sensitize primary sensory neurons and leads to central sensitization and also facilitate the release of pain-related neuropeptides
-Upregulated in AD brain; promotes inflammatory cytokine release, increase ROS, may increase Aβ deposition
Scientific Papers found: Click to Expand⟱
5405- ASA,    Exploring Aspirin’s Potential in Cancer Prevention: A Comprehensive Review of the Current Evidence
- Review, Var, NA
Risk↓, emerging evidence suggests that aspirin may reduce the risk of certain cancers, particularly colorectal cancer (CRC).
COX1↓, Aspirin’s anticancer effects are primarily attributed to its cyclooxygenase (COX) enzyme inhibition, which decreases prostaglandin E2 (PGE2) levels and disrupts cancer-related signaling pathways.
PGE2↓,
Inflam↓, Aspirin is a versatile medication commonly used as an analgesic, anti-inflammatory, antipyretic, and antiplatelet agent [2,3].
*AntiAg↓,
PI3K↓, By irreversibly inhibiting COX-2, aspirin reduces PGE2 levels, thereby decreasing the activation of cancer-related signaling pathways such as PI3K/AKT (phosphatidylinositol 3-kinase/protein kinase B) and ERK and promoting apoptosis in cancer cells ​
Akt↓,
Risk↓, For pancreatic cancer, aspirin for at least five years significantly reduces the risk of death, though this protective effect becomes apparent only after a five-year lag period [39].

5415- ASA,    The Anti-Metastatic Role of Aspirin in Cancer: A Systematic Review
- Review, Var, NA
TumMeta↓, The included studies demonstrated that aspirin suppresses metastatic dissemination across multiple cancer types through coordinated platelet-dependent and tumor-intrinsic mechanisms.
COX1↓, Aspirin consistently inhibited platelet aggregation and COX-1-dependent TXA2 production, disrupting platelet–tumor cell interactions, intravascular metastatic niche formation, and platelet-mediated immune suppression.
TXA2↓,
AntiAg↑, Beyond platelet effects, aspirin suppressed EMT, migration, and invasion through modulation of EMT transcriptional regulators and inflammatory signaling pathways.
EMT↓,
TumCMig↓,
TumCI↓,
AMPK↑, Additional mechanisms included activation of AMPK, inhibition of c-MYC signaling, regulation of redox-responsive pathways and impairment of anoikis resistance.
cMyc↓,
PGE2↓, Importantly, oral aspirin (20 mg/kg/day; human-equivalent ≈ 150 mg/day), administered before tumor cell injection, prevented platelet-induced metastatic enhancement and suppressed TXA2 and PGE2 production.
Dose↑, medium and high doses of aspirin reduced pulmonary metastatic burden by more than 50%, whereas low-dose aspirin was ineffective.
RadioS↑, Wang et al. [45] demonstrated that low-dose aspirin suppresses radiotherapy-induced release of immunosuppressive exosomes in breast cancer, restoring NK-cell proliferation and enhancing antitumor immunity in vivo.
PD-L1↓, Similarly, Xiao et al. [46] showed that aspirin epigenetically downregulates PD-L1 expression by inhibiting KAT5-dependent histone acetylation, thereby restoring T-cell activation
E-cadherin↑, Aspirin restored E-cadherin expression and suppressed EMT regulators, including Slug, vimentin, Twist, MMP-2, and MMP-9.
EMT↓,
Slug↓,
Vim↓,
Twist↓,
MMP2↓,
MMP9↓,
other↑, definitive conclusions regarding clinical efficacy across cancer types cannot yet be drawn. Nevertheless, the consistency of mechanistic signals across experimental systems supports further investigation of aspirin as a low-cost adjunct in oncology

1218- VitC,  ASA,    Ascorbic acid enhances the inhibitory effect of aspirin on neuronal cyclooxygenase-2-mediated prostaglandin E2 production
- in-vitro, GBM, SK-N-SH
PGE2↓,
COX2↓, owing to its antioxidant properties


* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


Core Metabolism/Glycolysis ⓘ

AMPK↑, 1,   cMyc↓, 1,  

Cell Death ⓘ

Akt↓, 1,  

Transcription & Epigenetics ⓘ

other↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

EMT↓, 2,   PI3K↓, 1,  

Migration ⓘ

AntiAg↑, 1,   E-cadherin↑, 1,   MMP2↓, 1,   MMP9↓, 1,   Slug↓, 1,   TumCI↓, 1,   TumCMig↓, 1,   TumMeta↓, 1,   Twist↓, 1,   Vim↓, 1,  

Angiogenesis & Vasculature ⓘ

TXA2↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX1↓, 2,   COX2↓, 1,   Inflam↓, 1,   PD-L1↓, 1,   PGE2↓, 3,  

Drug Metabolism & Resistance ⓘ

Dose↑, 1,   RadioS↑, 1,  

Clinical Biomarkers ⓘ

PD-L1↓, 1,  

Functional Outcomes ⓘ

Risk↓, 2,  
Total Targets: 26

Pathway results for Effect on Normal Cells:


Migration ⓘ

AntiAg↓, 1,  
Total Targets: 1

Scientific Paper Hit Count for: PGE2, Prostaglandin E2
3 Aspirin -acetylsalicylic acid
1 Vitamin C (Ascorbic Acid)
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:1  Target#:248  State#:%  Dir#:%
  wNotes=on  sortOrder:rid,rpid

 

Home Page